Influence of long-term administration of lactulose and Saccharomyces boulardii on the colonic generation of phenolic compounds in healthy human subjects - PubMed (original) (raw)
Randomized Controlled Trial
Influence of long-term administration of lactulose and Saccharomyces boulardii on the colonic generation of phenolic compounds in healthy human subjects
Vicky De Preter et al. J Am Coll Nutr. 2006 Dec.
Abstract
Objective: Proteins are degraded in the colon by bacterial fermentation into potentially toxic metabolites such as phenolic compounds. The aim of the present study was to investigate whether long-term administration of lactulose or Saccharomyces boulardii cells would result in a lower protein degradation. In addition, the influence of a long-term dietary intake on different gastrointestinal parameters was investigated.
Methods: The effect of long-term intervention of the substrates was evaluated in a randomized, cross-over study in 43 healthy volunteers. At the start of the study and at the end of each 4-week treatment period, urine was collected during 48 h in different fractions and faeces during 72 h. Breath test samples and blood samples were taken to study gastrointestinal parameters.
Results: No influence of long-term administration of both substrates was found on GE, OCTT and serum lipids. A significant decrease in small intestinal permeability was found after long-term dietary intervention with lactulose. Long-term administration of lactulose significantly decreased urinary p-cresol excretion, but did not lower fecal p-cresol excretion. No significant effects were observed after S. boulardii intake.
Conclusion: The results obtained in present study have indicated that colonic amino acid fermentation can be reduced by the administration of lactulose as a fermentable carbohydrate.
Similar articles
- Effect of lactulose and Saccharomyces boulardii administration on the colonic urea-nitrogen metabolism and the bifidobacteria concentration in healthy human subjects.
De Preter V, Vanhoutte T, Huys G, Swings J, Rutgeerts P, Verbeke K. De Preter V, et al. Aliment Pharmacol Ther. 2006 Apr 1;23(7):963-74. doi: 10.1111/j.1365-2036.2006.02834.x. Aliment Pharmacol Ther. 2006. PMID: 16573799 Clinical Trial. - Intestinal transport and fermentation of resistant starch evaluated by the hydrogen breath test.
Olesen M, Rumessen JJ, Gudmand-Høyer E. Olesen M, et al. Eur J Clin Nutr. 1994 Oct;48(10):692-701. Eur J Clin Nutr. 1994. PMID: 7835324 Clinical Trial. - Effects of therapeutic doses of lactulose vs. polyethylene glycol on isotopic colonic transit.
Jouët P, Sabate JM, Flourie B, Cuillerier E, Gambini D, Lemann M, Jian R, Coffin B. Jouët P, et al. Aliment Pharmacol Ther. 2008 May;27(10):988-93. doi: 10.1111/j.1365-2036.2008.03654.x. Epub 2008 Feb 18. Aliment Pharmacol Ther. 2008. PMID: 18284652 Clinical Trial. - Lactulose: Patient- and dose-dependent prebiotic properties in humans.
Ruszkowski J, Witkowski JM. Ruszkowski J, et al. Anaerobe. 2019 Oct;59:100-106. doi: 10.1016/j.anaerobe.2019.06.002. Epub 2019 Jun 5. Anaerobe. 2019. PMID: 31176002 Review. - Functional analysis of colonic bacterial metabolism: relevant to health?
Hamer HM, De Preter V, Windey K, Verbeke K. Hamer HM, et al. Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1;302(1):G1-9. doi: 10.1152/ajpgi.00048.2011. Epub 2011 Oct 20. Am J Physiol Gastrointest Liver Physiol. 2012. PMID: 22016433 Free PMC article. Review.
Cited by
- Microbiota-related metabolites fueling the understanding of ischemic heart disease.
Fan Y, Ying J, Ma H, Cui H. Fan Y, et al. Imeta. 2023 Feb 26;2(2):e94. doi: 10.1002/imt2.94. eCollection 2023 May. Imeta. 2023. PMID: 38868424 Free PMC article. - Two-sample Mendelian randomization to study the causal association between gut microbiota and atherosclerosis.
Jiang S, Yu C, Lv B, He S, Zheng Y, Yang W, Wang B, Li D, Lin J. Jiang S, et al. Front Immunol. 2024 Jan 12;14:1282072. doi: 10.3389/fimmu.2023.1282072. eCollection 2023. Front Immunol. 2024. PMID: 38283337 Free PMC article. - Diversified Shifts in the Cross Talk between Members of the Gut Microbiota and Development of Coronary Artery Diseases.
Zhang T, Ren H, Du Z, Zou T, Guang X, Zhang Y, Tian Y, Zhu L, Yu J, Yu X, Zhang Z, Dai H. Zhang T, et al. Microbiol Spectr. 2022 Dec 21;10(6):e0280422. doi: 10.1128/spectrum.02804-22. Epub 2022 Oct 27. Microbiol Spectr. 2022. PMID: 36301099 Free PMC article. - Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases.
Mutalub YB, Abdulwahab M, Mohammed A, Yahkub AM, Al-Mhanna SB, Yusof W, Tang SP, Rasool AHG, Mokhtar SS. Mutalub YB, et al. Foods. 2022 Aug 25;11(17):2575. doi: 10.3390/foods11172575. Foods. 2022. PMID: 36076760 Free PMC article. Review. - Protective Effect of Fermented Camel Milk Containing Bifidobacterium longum BB536 on Blood Lipid Profile in Hypercholesterolemic Rats.
El-Zahar KM, Hassan MFY, Al-Qaba SF. El-Zahar KM, et al. J Nutr Metab. 2021 Oct 29;2021:1557945. doi: 10.1155/2021/1557945. eCollection 2021. J Nutr Metab. 2021. PMID: 34745660 Free PMC article.